14:35:09 EDT Tue 16 Apr 2024
Enter Symbol
or Name
USA
CA



Imagin Medical Inc
Symbol IME
Shares Issued 139,060,278
Close 2019-10-15 C$ 0.05
Market Cap C$ 6,953,014
Recent Sedar Documents

Imagin begins social media campaigns

2019-10-17 16:07 ET - News Release

Mr. Jim Hutchens reports

IMAGIN MEDICAL ANNOUNCES SOCIAL MEDIA CAMPAIGN LAUNCH

Imagin Medical Inc. has launched new social media campaigns through Twitter, Facebook and LinkedIn.

The primary goal of these new campaigns is to provide patients suffering from bladder cancer, their loved ones and the general public with an on-line resource to better understand the disease state, as well as to provide access to up-to-date information on this disease.

Imagin Medical intends to help patients gain control of their journey through education and innovation in the field of bladder cancer.

In addition to educational resources, Imagin Medical will be leveraging these digital channels to keep investors up to date on its corporate progress and company activities. Members of the company's executive team and scientific advisory board will also regularly contribute thought leadership content.

The company is run by an experienced Boston-based medical device executive team that has significant surgical endoscopy experience gained over decades of helping define how minimally invasive surgery is performed today.

Jim Hutchens, president and chief executive officer, commented: "Imagin is actively building a digital market awareness ecosystem that will help not only patients, but also keep our investors informed. We encourage readers to follow us on Facebook, Twitter and LinkedIn, or visit our website for further information."

About Imagin Medical Inc.

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS). The company's first product, the i/Blue imaging system, is based on advanced optics and light sensors, and employs patented ultrasensitive imaging technology. The company's initial focus is bladder cancer.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.